Interestingly, high Amigo2 was significantly associated with poor relapse-free survival in patients with TP53 WT and not in patients with TP53 mutant breast cancers (Fig 5G), [43] identifying an intriguing relationship between TP53 status and Amigo2 biology in breast cancer. This evidence concerns the gene AMIGO2 and breast carcinoma.